Furthermore, we revealed the critical role of FXR in CKD progression post-AKI, which indicates that FXR may be a pharmacological target in the early stages of kidney damage and that it can protect against the progression of AKI to CKD. The gene discussed is NR1H4; the disease is chronic kidney disease.